Activation of the protease-activated receptors (PAR) 2 or the transient receptor potential vanilloid type 1 (TRPV1) channels expressed in cardiac sensory afferents containing calcitonin gene-related peptide (CGRP) and/or substance P (SP) has been proposed to play a protective role in myocardial ischemia/reperfusion (I/R) injury. However, the interaction between PAR2 and TRPV1 is largely unknown. Using gene-targeted suggesting that PAR2-mediated protection is TRPV1-dependent and -independent, and that dysfunctional TRPV1 impairs PAR2 action. PAR2 activation of the PKCε or PKA pathway stimulates or sensitizes TRPV1 in WT hearts, leading to the release of CGRP and SP that contribute at least in part to PAR2-induced cardiac protection against I/R injury.
36). We and others have recently shown that TRPV1 plays a key role in protecting the heart from I/R injury (34, 39, 43) . TRPV1-positive sensory nerves integrate and respond to stimuli generated or released during myocardial ischemia (29) by transmitting signals to the central nervous system as well as releasing sensory neurotransmitters including SP and CGRP (13, 14) that have been shown to protect the heart from ischemic injury (18, 37, 41) . While TRPV1 and PAR2 have been independently shown to protect the heart, the link and interaction between TRPV1 and PAR2 in cardiac protection remain unknown.
A growing body of evidence indicates that PKC and PKA play a crucial role in cardiac protection signaling transduction pathways (27, 33) . PKCε and PKA co-localize with PAR2 in DRG neurons, and PAR2 activation promotes translocation of PKCε and PKA catalytic subunits from the cytosol to the plasma membrane (1, 2, 4). In addition, PKC and PKA may induce or potentiate TRPV1 activity (4, 19, 32) . However, the inter-relation between PKC/PKA and PAR2/TRPV1 mediated cardiac protection is unknown. Using gene-targeted TRPV1-null mutant (TRPV1 -/-) and wild-type (WT) mice, the aim of the present study was to investigate 1) whether PAR2-mediated cardiac protection is TRPV1-dependent; 2) whether PAR2-mediated TRPV1 activation is via activation of PKCε and/or PKA pathways; and 3) whether PAR2-mediated, TRPV1-dependent cardiac protection is the result of SP and/or CGRP release.
Materials and Methods

Immunofluorescence assay of TRPV1, PAR2, PKCε and PKAc in the heart
The left ventricular tissue blocks were cut to a thickness of 10µm. The tissues sections were incubated with the primary antibody (Santa Cruz): goat anti-TRPV1 (1:2500); rabbit anti-PAR2 (1:50); goat anti-PKCε (1:50); or rabbit anti-PKAα cat (PKAc) (1:200) for 24 hour at 4°C. The sections were then incubated with anti-rabbit or anti-goat conjugated to cyanine 3 (1:200) or with horseradish peroxidase-conjugated donkey anti-goat IgG secondary antibody (1:200; Jackson ImmunoResearch). The sections were subsequently incubated with FITC-conjugated to tyramide (TSA kit, PerkinElmer Life Sciences) based on the protocol recommended by the manufacturer. In controls, primary antibodies were pre-absorbed with 10 μmol/L peptides used for immunization for 48 hour at 4°C.
Langendorff Heart Preparation and Measurements of Cardiac Function
Male TRPV1 -/-strain B6.129S4-TRPV1 tm1Jul and control WT strain C57BL/6J mice, to which TRPV1 -/ -mice were backcrossed for at least six generation, were used. Mice were heparinized (500 U/kg i.p.) and anesthetized with pentobarbital sodium (50 mg/kg i.p.).
Hearts from TRPV1 -/-and WT mice were cannulated and retrogradely perfused at 37 Analyzer via a pressure transducer. The recovery rate of coronary flow (% CF) was continuously measured using an ultrasonic flow probe placed in the aortic perfusion line.
Hearts were paced at 400 bpm except during sustained global ischemia to avoid inducing excessive ventricular tachyarrhythmia during reperfusion, and pacing was reinitiated 2 minutes after reperfusion. The maximum rate of LV pressure development (dP/dt) during isovolumic contraction and left ventricular developed pressure (LVDP) were used as indices of LV systolic function; LVEDP were used as indices of LV diastolic function. The experiments were approved by the Michigan State University Animal Care and Use Committee.
Experimental protocols
All hearts were allowed to stabilize for 25 minutes, and then perfused at 1% of the coronary flow rate with (1) antagonists/inhibitors were added to the perfusate 5 minutes before adding SLIGRL and continuously perfused for additional 5 minutes after SLIGRL perfusion. Hearts were subsequently subjected to 35 minutes of no-flow normothermic global ischemia followed by 40-minutes of reperfusion.
Measurement of lactate dehydrogenase (LDH) release
In addition to the measurement of cardiac function, cardiac injury was assessed by measurement of LDH release. Perfusion effluent was collected during the first 5 to 15 minutes of I/R and stored at 80°C until analysis. Total LDH levels were determined with the use of a cytotoxicity detection kit (Roche applied science). The data were expressed as absorbance units released per milliliter per minute per gram of wet heart tissues.
Evaluation of myocardial infarct size
Risk area and infarct size were measured 40 min after post-ischemia reperfusion. Hearts were perfused for 10 min at a flow rate of 2 ml/min with a 1% 2, 3, 5-triphenyltetrazolium chloride (TTC) dissolved in Krebs buffer. TTC stains all living tissue brick red and leaves the infarct area unstained (white). Hearts were then removed from the cannula and sliced perpendicularly along the long axis from apex to base in 2-mm sections. Sections were incubated for another 10 min at 37°C in 1% TTC. Once the color was established, the slices were fixed in 10% formalin for 48 hours and weighed. Both sides of each slice were photographed and delineated with photos that were quantified with Image J version 1.37v
(NIH). Since hearts were subjected to global ischemia, the total cross-sectional areas were defined as the total risk areas. The ratio of the infarct area to the total risk area (% infarct size) of both sides of each slice was calculated and multiplied by the weight of the slice.
Measurement of SP and CGRP
WT and TRPV1 -/-hearts were cut into pieces and put into tubes containing Krebs-Henseleit buffer with 1µM phosphoramidon and 1µM captopril that were saturated with 95% O 2 -5% CO 2 at 37°C continuously for 60 min (the stabilization period). SLIGRL (SL, 10 -6 M) or LSIGRL control (LS, 10 -6 M) was then added and incubated for 60 min. To determine the role of PKCε and PKA in SLIGRL-induced SP and CGRP release, PKCε V1-2 (10 -4 M), a selective PKCε inhibitor, or H-89 (5×10 -6 M), a selective PKA inhibitor, was added 5 min before adding SLIGRL. The samples were purified and analyzed with the rat CGRP and SP radioimmunoassay kits (Peninsula Laboratories Inc.) for determination of CGRP and SP release that was normalized by the wet heart weight.
Statistical Analysis
All values are expressed as mean ± SEM. 
Results
Co-localization of TRPV1, PAR2, PKCε and PKAc in the heart
Immunofluorescence assay showed that, while it was absent in TRPV1 -/-hearts (Fig 1,   A1 ), positive TRPV1 immunostaining was detected on the epicardial surface, blood vessels, and perivascular nerves in WT hearts (Fig 1, A2 ). Similar patterns of PAR2 immunostaining were detected in WT and TRPV1 -/-hearts (Fig 1, B1 -2). Western blot showed that there was no significant difference in the expression of PAR2 between WT and TRPV1 -/-hearts (supplementary data), indicating that ablation of TRPV1 may not affect PAR2 expression. TRPV1 and PAR2 co-expressed mainly on the epicardial surface and blood vessels in WT but not TRPV1 -/-hearts (Fig 1, C1 -2), which is consistent with previous findings (7, 15, 22) 
SLIGRL protection against I/R injury was impaired in TRPV1 -/-hearts
There were no statistically significant differences in hemodynamics between groups under baseline conditions. After I/R, SLIGRL pretreatment groups improved recovery of % CF, dP/dt, and LVDP and inhibited the increase in LVEDP in both WT and TRVR1 -/-hearts compared to their respective controls ( Fig. 2) , indicating that PAR2 mediated cardiac protection is TRPV1-dependent and -independent.
Blockade of the CGRP receptor suppressed SLIGRL protection in WT hearts
To determine if endogenous CGRP plays a role in SLIGRL-induced cardiac protection, CGRP 8-37 (10 -6 M), a selective CGRP receptor antagonist, was given and showed to block SLIGRL-induced cardiac protection by inhibiting recovery of % CF, dP/dt, and LVDP and increasing LVEDP in WT but not TRVR1 -/-hearts when compared to their respective controls ( Fig. 3) . These results suggest that PAR2 mediated cardiac protection is through, at least in part, CGRP receptor activation by its agonist release upon TRPV1 activation.
Higher (10 -5 M) or lower (10 -7 M) concentrations of CGRP 8-37 had similar effects on post-I/R recovery as that evoked by 10 -6 M CGRP in WT hearts (data not shown).
Moreover, 10 -6 M CGRP 8-37 had no effect on cardiac function in the absence of I/R injury in WT hearts.
Blockade of the SP receptor impaired SLIGR protection in WT hearts
The effect of endogenous SP on SLIGRL-inducing cardiac protection was assessed by pretreatment of the hearts with the NK-1 receptor antagonist, RP67580 ( M RP67580 in WT hearts (data not shown). In addition, 10 -7 M RP67580 had no effect on cardiac function in the absence of I/R injury in WT hearts.
Blockade of PKC, PKCε, or PKA impaired SLIGR protection in WT hearts
The effect of PKCε and PKA activation on SLIGRL-induced cardiac protection was 
Measurements of LDH and infarct area
LDH levels and the infarct area after I/R were significantly lower in WT and TRPV1 -/-hearts treated with SLIGRL compared to their respective control groups (Figs 7 and 8).
Moreover, LDH levels and the infarct area after I/R were significantly smaller in WT hearts treated with SLIGRL than in TRPV1 -/-hearts treated with SLIGRL (Figs 7, 8) , indicating that SLIGRL protects the hearts from I/R injury in both WT and TRPV1 -/-hearts but its protection is impaired when TRPV1 gene is deleted.
Measurements of SP and CGRP release
The release of SP and CGRP at the baseline (LSIGRL control) was not different between WT and TRPV1 -/-hearts (Fig. 9 ). SP and CGRP release increased remarkably in WT but not TRPV1 -/-hearts treated with SLIGRL ( Fig.9 ), indicating that SLIGRL-induced SP and CGRP release is TRPV1-dependent. Inhibiting PKCε or PKA with PKCε V1-2 (10 -4 M) or H-89 (5 × 10 -6 M), respectively, abolished SLIGRL-induced SP and CGRP release in WT hearts ( Fig.9 ), indicating that these pathways mediate SLIGRL-induced SP and CGRP release.
Discussion
The aim of the present study was to define whether TRPV1 plays a role in PAR2 induced cardiac protection; and if so, what mechanisms underlie the TRPV1-dependent pathway of PAR2 protection. Indeed, interaction between TRPV1 and PAR2 has been shown in which PAR2 agonist-induced vasodilation was attenuated by a selective antagonist of TRPV1, capsazepine (21). However, the limitation of the pharmacologic approaches is that capsazepine has been shown to induce cellular apoptosis and necrosis via a non-receptor mediated mechanism (3). To avoid the drawback, the present study uses the hearts from TRPV1 gene knockout mice or WT mice to study.
Our data show that 1) TRPV1 co-expresses with PAR2, PKCε, or PKAc in cardiomyocytes, cardiac blood vessels, and perivascular nerves in WT but not TRPV1 -/-hearts, providing anatomical basis for TRPV1 and PAR2/ PKCε/PKAc interaction under pathophysiological conditions; 2) PAR2 activation improves cardiac recovery after I/R injury in both WT and TRPV1 -/-hearts, suggesting that PAR2-mediated protection is TRPV1-dependent and -/-mice, the fact that TRPV1 and PAR2 co-express in cardiac vessels and cardiomyocytes
indicates that TRPV1 and PAR2 may share common signaling pathways or act synergistically to protect the heart from I/R injury.
Indeed, the primary sequence of TRPV1 predicts several putative phosphorylation sites, 
